Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jun 23, 2026

Bio Spectrum | Can Precision Antibodies Deliver a Safer Future for Alzheimer's Patients?

May 11, 2026

Inside Precision Medicine - Stopping Neurodegeneration in Place with Vaccines

Oct 5, 2022

The ALS Curveball, Part II

Oct 5, 2022

The ALS Curveball, Part I

Aug 2, 2022

New Collaborative Research Grant will Support the Development of a Vaccine for Misfolded Protein Diseases

Jul 18, 2022

A Tale of Tangles We Weave, Chapter 4

Jul 14, 2022

ProMIS rings Nasdaq closing bell, July 13, 2022

Mar 17, 2022

A Tale Of Tangles We Weave

Jan 11, 2022

Stimulating the Next Generation of AD Treatment

Oct 5, 2021

Funding boost expands MND research in our region

rss_feed RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy